TEVA heads into its May 6 Q1 results on the back of a rare wave of unanimous bullishness from the Street, with the stock already up 14% on the week and 16% over the past month to $34.95.
The analyst signal here is unusually clean. Four separate firms — JP Morgan, UBS, Piper Sandler, and Truist Securities — all raised price targets on April 30, the day before the print, with none cutting ratings. JP Morgan's Chris Schott lifted his target from $35 to $40 while maintaining Overweight. UBS moved to $42 from $36. Truist went furthest, pushing to $45. The consensus mean now sits at $40.09, roughly 15% above the current price, suggesting the Street sees room to run even after the recent rally. Goldman Sachs had already moved to $45 back in February. The direction of travel has been one-way for months.
The bull case rests on Teva's position as the dominant global generics manufacturer and on the growth potential of its biosimilars pipeline — particularly Duvakitug, its TL1A-targeting candidate. Bears point to a more familiar list of concerns: Copaxone patent pressure, intensifying generic competition, a debt load built up through past acquisitions, and a steady drip of legal exposure. With the PE multiple now running at 13.1x and EV/EBITDA at 10.6x — both up roughly 2.3 turns over the past month as the stock re-rated higher — the question heading into the print is whether the earnings delivery can validate that expansion.
Options positioning has grown slightly more defensive into the release. The put/call ratio is running at 0.53, more than two standard deviations above its 20-day average of 0.48, a modest but notable uptick in demand for downside protection. Short interest, by contrast, tells a calm story. SI is 2.7% of the free float — up about 16% in raw share terms over the past week, but with borrow costs just 0.35% and availability extremely loose at over 3,200% of short interest, there is no meaningful squeeze pressure or conviction among short sellers. Institutional ownership is broad and stable, with Norges Bank, Migdal, BlackRock, and Vanguard all among the top holders and no dramatic departures evident in recent filings.
The May 6 print is therefore less a test of whether Teva's turnaround is real, and more a test of whether the pace of execution on biosimilars and debt reduction can justify a multiple that has already moved meaningfully in anticipation.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
